Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Paul Edward Sax, M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. M01RR002635 (GOTTLIEB, GARY L) Dec 1, 1984 - Mar 31, 2010
    General Clinical Research Center
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, Esser S, Huang H, Koethe JR, Martin H, McComsey GA, Orkin C, Post FA, Rockstroh JK, Sax PE, Stellbrink HJ, Waters L, Wei X, Lake JE. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. Clin Infect Dis. 2021 10 20; 73(8):1440-1451. PMID: 33987636.
    Citations: 2     Fields:    
  2. Llibre JM, Sax PE. Reassessing oral lead-in for injectable long-acting HIV therapy. Lancet HIV. 2021 Nov; 8(11):e660-e661. PMID: 34656209.
    Citations:    Fields:    
  3. Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, Llibre JM, Camazine M, Díaz-De Santiago A, Carlucci PM, Zacharioudakis IM, Rahimian J, Wanjalla CN, Slim J, Arinze F, Kratz AMP, Jones JL, Patel SM, Kitchell E, Francis A, Ray M, Koren DE, Baddley JW, Hill B, Sax PE, Chow J. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis. 2021 10 05; 73(7):e1964-e1972. PMID: 32905581.
    Citations: 30     Fields:    Translation:HumansCells
  4. Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, Kuritzkes DR, Sax PE, Wohl DA, Casciano R, Hodgkins P, Haubrich R. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis. 2021 Oct 01. PMID: 34596223.
    Citations:    Fields:    
  5. Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, Brainard DM, Martin H. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2021 07 15; 73(2):e485-e493. PMID: 32668455.
    Citations: 5     Fields:    Translation:HumansCells
  6. Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clin Infect Dis. 2021 07 01; 73(1):33-42. PMID: 33336698.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  7. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2. Ann Intern Med. 2021 07; 174(7):1037. PMID: 34280346.
    Citations:    Fields:    Translation:Humans
  8. Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, Jean-Philippe P, Johnston B, Krotje C, Fairlie L, Hoffman RM, Sax PE, Moyo S, Chakhtoura N, Stringer JS, Masheto G, Korutaro V, Cassim H, Mmbaga BT, João E, Hanley S, Purdue L, Holmes LB, Momper JD, Shapiro RL, Thoofer NK, Rooney JF, Frenkel LM, Amico KR, Chinula L, Currier J. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021 04 03; 397(10281):1276-1292. PMID: 33812487.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  9. Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. Ann Intern Med. 2021 06; 174(6):803-810. PMID: 33683930.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  10. Saag MS, Gandhi RT, Sax PE. Antiretroviral Drug Recommendations for HIV Treatment and Prevention-Reply. JAMA. 2021 03 02; 325(9):889-890. PMID: 33651088.
    Citations:    Fields:    Translation:Humans
  11. Paltiel AD, Zheng A, Sax PE. Clinical and Economic Impact of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. medRxiv. 2021 Feb 08. PMID: 33564779.
  12. Cevik M, Haque SA, Manne-Goehler J, Kuppalli K, Sax PE, Majumder MS, Orkin C. Gender disparities in coronavirus disease 2019 clinical trial leadership. Clin Microbiol Infect. 2021 Jul; 27(7):1007-1010. PMID: 33418021.
    Citations: 2     Fields:    Translation:Humans
  13. Curtis MR, Sax P. Web Exclusive. Annals for Hospitalists Inpatient Notes - Remdesivir-Making Sense of Emerging Evidence. Ann Intern Med. 2020 Dec 15; 173(12):HO2-HO3. PMID: 33316192.
    Citations:    Fields:    
  14. Jilg N, Garcia-Broncano P, Peluso M, Segal FP, Bosch RJ, Roberts-Toler C, Chen SMY, Van Dam CN, Keefer MC, Kuritzkes DR, Landay AL, Deeks S, Yu XG, Sax PE, Li JZ. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. J Infect Dis. 2020 11 09; 222(11):1837-1842. PMID: 32496516.
    Citations: 1     Fields:    Translation:HumansCells
  15. Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, Smith DM, Benson CA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020 10 27; 324(16):1651-1669. PMID: 33052386.
    Citations: 23     Fields:    Translation:HumansCellsPHPublic Health
  16. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2021 01; 174(1):69-79. PMID: 32941052.
    Citations: 108     Fields:    Translation:HumansPHPublic Health
  17. Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020 09 12; 71(6):1379-1389. PMID: 31606734.
    Citations: 61     Fields:    Translation:Humans
  18. Pearson JC, Dionne B, Richterman A, Vidal SJ, Weiss Z, Velásquez GE, Marty FM, Sax PE, Yawetz S. Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa415. PMID: 33094118.
    Citations: 2     
  19. Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S63-S69. PMID: 32645158.
    Citations:    Fields:    Translation:Humans
  20. Barnes M, Sax PE. Challenges of "Return to Work" in an Ongoing Pandemic. N Engl J Med. 2020 08 20; 383(8):779-786. PMID: 32558484.
    Citations: 19     Fields:    Translation:HumansCellsPHPublic Health
  21. Cevik M, Orkin C, Sax PE. Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases. Open Forum Infect Dis. 2020 Jun; 7(6):ofaa202. PMID: 32587877.
    Citations: 3     
  22. Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020 06; 7(6):e389-e400. PMID: 32504574.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  23. Sun X, Hua S, Gao C, Blackmer JE, Ouyang Z, Ard K, Ciaranello A, Yawetz S, Sax PE, Rosenberg ES, Lichterfeld M, Yu XG. Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation. Nat Commun. 2020 05 15; 11(1):2421. PMID: 32415086.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  24. Li JZ, Segal FP, Bosch RJ, Lalama CM, Roberts-Toler C, Delagreverie H, Getz R, Garcia-Broncano P, Kinslow J, Tressler R, Van Dam CN, Keefer M, Carrington M, Lichterfeld M, Kuritzkes D, Yu XG, Landay A, Sax PE. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020 04 10; 70(8):1636-1642. PMID: 31131858.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  25. Hyle EP, Scott JA, Sax PE, Millham LRI, Dugdale CM, Weinstein MC, Freedberg KA, Walensky RP. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States. Clin Infect Dis. 2020 03 17; 70(7):1353-1363. PMID: 31055599.
    Citations: 5     Fields:    Translation:HumansCells
  26. Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Clin Infect Dis. 2020 03 17; 70(7):1336-1343. PMID: 31121013.
    Citations: 2     Fields:    Translation:HumansCells
  27. Taiwo BO, Quiñones-Mateu ME, Smith K, Zheng L, Gulick R, Nyaku AN, Sax PE, Ha B, Kumwenda J, Olefsky M, Godfrey C, Wallis C. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. AIDS Res Hum Retroviruses. 2020 04; 36(4):254-255. PMID: 31914799.
    Citations:    Fields:    Translation:HumansCells
  28. Richterman A, Sax PE. Antiretroviral therapy in older people with HIV. Curr Opin HIV AIDS. 2020 03; 15(2):118-125. PMID: 31990705.
    Citations: 2     Fields:    Translation:Humans
  29. Patel SV, Jayaweera DT, Althoff KN, Eron JJ, Radtchenko J, Mills A, Moyle G, Santiago S, Sax PE, Gillman J, Mounzer K, Elion RA, Huhn GD. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PLoS One. 2020; 15(2):e0228847. PMID: 32053682.
    Citations: 5     Fields:    Translation:HumansCells
  30. Millham LRI, Scott JA, Sax PE, Shebl FM, Reddy KP, Losina E, Walensky RP, Freedberg KA. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):148-156. PMID: 31929403.
    Citations:    Fields:    Translation:Humans
  31. Corsi-Vasquez G, Ostrosky-Zeichner L, Pilkington EF, Sax PE. Point-Counterpoint: Should Serum ß-d-Glucan Testing Be Used for the Diagnosis of Pneumocystis jirovecii Pneumonia? J Clin Microbiol. 2019 12 23; 58(1). PMID: 31434728.
    Citations: 2     Fields:    Translation:HumansAnimals
  32. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020 01; 7(1):e16-e26. PMID: 31740348.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  33. Sax PE. Nearly Two Decades Later, Exciting Progress in HIV, But Challenges Remain. Infect Dis Clin North Am. 2019 09; 33(3):xiii-xiv. PMID: 31395148.
    Citations:    Fields:    Translation:Humans
  34. Gupta SK, Post FA, Arribas JR, Eron JJ, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019 07 15; 33(9):1455-1465. PMID: 30932951.
    Citations: 24     Fields:    Translation:Humans
  35. Braun DA, Henderson GV, Sax PE, Miller AL, Loscalzo J. A Disturbing Decline. N Engl J Med. 2019 Jun 06; 380(23):2257-2262. PMID: 31167056.
    Citations: 1     Fields:    Translation:HumansCells
  36. Braun DA, Simchowitz B, Henderson GV, Sax PE, Vaidya A. A Disturbing Decline. N Engl J Med. 2019 May 30; 380(22):e42. PMID: 31141638.
    Citations:    Fields:    Translation:Humans
  37. Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 06; 6(6):e364-e372. PMID: 31068272.
    Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
  38. Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500?000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019 05 01; 74(5):1376-1380. PMID: 30668695.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  39. Bourque DL, Solomon DA, Sax PE. Health Considerations for HIV-Infected International Travelers. Curr Infect Dis Rep. 2019 Apr 12; 21(5):16. PMID: 30980287.
  40. Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study. Ann Intern Med. 2019 05 07; 170(9):614-625. PMID: 30934067.
    Citations: 16     Fields:    Translation:Humans
  41. Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrob Agents Chemother. 2019 04; 63(4). PMID: 30642925.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  42. Hulgan T, Ramsey BS, Koethe JR, Samuels DC, Gerschenson M, Libutti DE, Sax PE, Daar ES, McComsey GA, Brown TT. Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. . 2019 03 01; 80(3):358-366. PMID: 30531304.
    Citations: 3     Translation:HumansCells
  43. Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, Fichtenbaum CJ, Wilkin T, Benson CA, Koletar SL, Lorenzo-Redondo R, Taiwo BO. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis. 2019 Mar; 6(3):ofz056. PMID: 30895201.
    Citations: 2     
  44. Hale TM, Guardigni V, Roitmann E, Vegreville M, Brawley B, Woodbury E, Storer TW, Sax PE, Montano M. Middle-Aged Men With HIV Have Diminished Accelerometry-Based Activity Profiles Despite Similar Lab-Measured Gait Speed: Pilot Study. JMIR Mhealth Uhealth. 2019 02 01; 7(2):e11190. PMID: 30707104.
    Citations: 4     Fields:    Translation:Humans
  45. Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019 02 01; 68(4):535-544. PMID: 30184165.
    Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
  46. Gianella S, Marconi VC, Berzins B, Benson CA, Sax P, Fichtenbaum CJ, Wilkin T, Vargas M, Deng Q, Oliveira MF, Moser C, Taiwo BO. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. . 2018 12 15; 79(5):e112-e114. PMID: 30383591.
    Citations: 2     Translation:HumansCells
  47. Cahn P, Sax PE, Squires K, Molina JM, Ratanasuwan W, Rassool M, Bloch M, Xu X, Zhou Y, Homony B, Hepler D, Teppler H, Hanna GJ, Nguyen BY, Greaves W. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. . 2018 08 15; 78(5):589-598. PMID: 29771789.
    Citations: 4     Translation:HumansCellsCTClinical Trials
  48. Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Wei X, Collins SE, Cheng A. Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. AIDS. 2018 07 31; 32(12):1723-1725. PMID: 29794828.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  49. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 07 24; 320(4):379-396. PMID: 30043070.
    Citations: 168     Fields:    Translation:Humans
  50. Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics. 2018 07; 28(7):179-187. PMID: 29847509.
    Citations: 2     Fields:    Translation:HumansCells
  51. Tran T, Guardigni V, Pencina KM, Amato AA, Floyd M, Brawley B, Mozeleski B, McKinnon J, Woodbury E, Heckel E, Li Z, Storer T, Sax PE, Montano M. Atypical Skeletal Muscle Profiles in Human Immunodeficiency Virus-Infected Asymptomatic Middle-Aged Adults. Clin Infect Dis. 2018 06 01; 66(12):1918-1927. PMID: 29293942.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  52. Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 05 17; 66(11):1689-1697. PMID: 29253097.
    Citations: 27     Fields:    Translation:HumansCells
  53. Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018 05 17; 66(11):1794-1797. PMID: 29293895.
    Citations: 21     Fields:    Translation:HumansCells
  54. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018 05; 5(5):e211-e220. PMID: 29592840.
    Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
  55. Buchanan AL, Hudgens MG, Cole SR, Mollan KR, Sax PE, Daar ES, Adimora AA, Eron JJ, Mugavero MJ. Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc. 2018 Oct; 181(4):1193-1209. PMID: 30555215.
    Citations: 19     
  56. Sax P, DeJesus E, Wohl D, DeMorin J, McColl D, Piontkowsky D, Cohen C, Wang H, White K, Callebaut C, Rhee M, Das M, Quirk E. Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA =1,000,000 copies/ml: a post hoc analysis of Phase III clinical trials. Antivir Ther. 2018; 23(1):95-99. PMID: 28799919.
    Citations: 1     Fields:    Translation: